Previous 10 | Next 10 |
2023-10-04 09:59:33 ET More on Health Care Select Sector SPDR September Labor Report Preview: Full Employment To Infinity Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Citi turns cautious on pharmaceuticals and biotech BofA Securities:...
2023-10-04 08:14:01 ET More on ALX Oncology, Ocean Biomedical, Inc., etc. ALX Oncology Holdings: Gilead News Creates A New Risk Ocean Biomedical: Some New Targets, No Clinical Data. Not For Me Biggest stock movers today: NextEra Energy Partners, WeWork, ALX Oncology,...
2023-10-03 12:12:51 ET DENVER, Colo., Oct 3, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; ALX Oncology Holdings (NASDAQ: ALXO), POINT Biopharma Global (NASDAQ: PNT), SciSparc (NASD...
2023-10-03 11:15:29 ET Shares of ALX Oncology (NASDAQ: ALXO) had skyrocketed by 53% as of 11:10 a.m. ET on Tuesday. The huge gain came after the immuno-oncology company announced positive interim results from a phase 2 study evaluating evorpacept in combination with trastuzuma, Cyra...
ALX Oncology Holdings Inc. (NASDAQ: ALXO) is one today's most active stocks by volume. So far today, approximately 25.04M shares of ALX Oncology Holdings Inc. have been exchanged, as compared to an average 30-day volume of 161.12k shares. ALX Oncology Holdings Inc., a clinical-stage immuno-onc...
2023-10-03 09:59:26 ET DENVER, Colo., Oct 3, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; ALX Oncology Holdings (NASDAQ: ALXO), POINT Biopharma Global (NASDAQ: PNT), SciSparc (NASDAQ: SPRC), ODDITY Tec...
2023-10-03 08:41:53 ET Gainers: Alx Oncology ( ALXO ) +116% . Vericity ( VERY ) +95% Strengthens Individual Insurance Presence in the United States with the Acquisition of Vericity. POINT Biopharma Global ( PNT ) +85% to acquire Point ...
2023-10-03 08:13:54 ET (24/7 MARKET NEWS) – ALX Oncology Holdings Inc., (NASDAQ: ALXO) published, this morning, positive prespecified interim Phase 2 data from its ASPEN-06 clinical trial, a randomized multi-center international study evaluating evorpacept, the Company’s CD47 ...
2023-10-03 06:56:20 ET More on ALX Oncology ALX Oncology Holdings: Gilead News Creates A New Risk ALX Oncology surges Phase 2 data for gastric cancer therapy Biggest stock movers today: ALX Oncology Holdings, Sibanye Stillwater and more Seeking Alpha’s...
-- Evorpacept is the first CD47 blocker to show activity in a global randomized study in solid tumors -- Interim efficacy results showed the confirmed overall response rate for evorpacept combination treatment was 52% compared to 22% for control treatment -- Company to host ...
News, Short Squeeze, Breakout and More Instantly...
ALX Oncology Holdings Inc. Company Name:
ALXO Stock Symbol:
NASDAQ Market:
ALX Oncology Holdings Inc. Website:
2024-07-09 15:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Evorpacept in combination with PADCEV ® , an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well tolerated Company to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering Cancer Center on ...
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management wi...